Elegrobart clinical trials
Also written VRDN-003.
How each study uses elegrobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VRDN-003
- 4
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Viridian Therapeutics, Inc. (4) · Zai Lab (Shanghai) Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test elegrobart, phase 3 first.
- Mar 2027A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseasePhase 3 · Zai Lab (Shanghai) Co., Ltd.
Studies
Open first, then newest update. How each study uses elegrobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseActive, not recruitingPhase 3Zai Lab (Shanghai) Co., Ltd.NCT07211776Written as ZL-1109 (VRDN-003)
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)Active, not recruitingPhase 3Viridian Therapeutics, Inc.NCT06625411Written as VRDN-003
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)Active, not recruitingPhase 3Viridian Therapeutics, Inc.NCT06625398Written as VRDN-003
- A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)CompletedPhase 3Viridian Therapeutics, Inc.NCT07155668Written as VRDN-003
- A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)Active, not recruitingPhase 3Viridian Therapeutics, Inc.NCT06812325Written as VRDN-003
Codes
What other systems call elegrobart · ClinicalTrials.gg INT018452
- UNII (FDA) XB49Z3T6CYELEGROBARTOne source FDA
- NCI Thesaurus C215280ElegrobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XB49Z3T6CY | ELEGROBART | One source FDA |
| NCI Thesaurus | C215280 | Elegrobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.